EPISODE · Jun 6, 2026 · 4 MIN
今天3分钟我们来聊聊慢阻肺能被干细胞逆转吗
from 源于细胞BioInsid的个人播客
慢阻肺是中国第三大致死病因，40岁以上每7人就有1例，其肺损伤不可逆。但干细胞或带来希望，它通过抗炎、抗氧化、分化修复和旁分泌效应四套机制发挥作用，多项临床研究显示安全性良好且能改善患者症状和生活质量。参考文献：Chen YT et al., Chinese Medical Journal, "Stem cell therapy for COPD" 综述（DOI: 10.1097/CM9.00000000000001596）常智杰团队，Signal Transduction and Targeted Therapy（IF=40.8），脐带MSC外泌体雾化治疗肺纤维化I期临床中国慢阻肺流行病学数据（40岁以上患病率13.7%）Global Burden of Disease Study（慢阻肺全球致死率第3位）《南华早报》2026年5月20日：NCR201 iPSC帕金森疗法报道AACR 2026：KIR-CAR T实体瘤数据原文来源：源于细胞BioInside（Carmens Vision）公众号前往小宇宙评论区与主播互动
Embed this episode
Ready to play
今天3分钟我们来聊聊慢阻肺能被干细胞逆转吗
0:00
4:08
1×
No transcript for this episode yet
Similar Episodes
No similar episodes found.
Similar Podcasts
Frequently Asked Questions
How long is this episode of 源于细胞BioInsid的个人播客?
This episode is 4 minutes long.
When was this 源于细胞BioInsid的个人播客 episode published?
This episode was published on June 6, 2026.
Can I download this 源于细胞BioInsid的个人播客 episode?
Yes. Use the download control on the episode player to save the publisher-provided media file.
URL copied to clipboard!